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Abstract Glucose-dependent insulinotropic polypeptide
(GIP), a gut peptide released in response to food intake
brings about secretion of insulin in a glucose-dependent
manner upon binding to its receptor, GIPR. GIP–GIPR has
emerged as a new vista for anti-diabetic drug discovery and
their interaction is being probed at the atomic level to aid
rational drug design. In order to probe this interaction on
cells, the current study attempts towards expressing
15N-labeled GIP using classical molecular biology tools.
We have developed a methodology to obtain GIP devoid of
extra amino acid(s); a prerequisite to the intended inter-
action study. The synthetic GIP cDNA with a Factor Xa
protease site at the N-terminus of GIP was inserted in the
vector pET32a(?); the fusion protein thus expressed was
eventually cleaved to obtain GIP. After successful Factor
Xa cleavage, the cleaved GIP was confirmed by western
blot. Subsequently, the (15N)GIP was obtained using the
aforementioned procedure and confirmed by MALDI-TOF.
Keywords Glucose-dependent insulinotropic polypeptide 
Affinity chromatography  Isotopic labeling  Recombinant
fusion protein  Factor Xa protease cleavage site  Diabetes
mellitus
Introduction
Glucose-dependent insulinotropic polypeptide (GIP) is a
peptide hormone released into the blood stream in response
to glucose and nutrients absorption from the intestine along
with glucagon like polypeptide-1 (GLP-1) (Drucker 2006;
McIntosh et al. 2009). Both peptides are known to exert
varied physiological actions on different body tissues with
the pancreas being the major effector. These peptides
interact with their respective G-protein-coupled receptors
present on the cell surface and activate the adenylate
cyclase signaling pathway. It brings about insulin secretion
from the pancreas in a glucose-dependent manner and thus
the name GIP. This pathway of insulin secretion is known
as entero-insular axis and the peptides as incretins. Due to
the glucose-dependent action, both GIP and GLP-1 have
attracted immense attention for the design of novel anti-
diabetics. In order to identify the key determinants of their
interaction, attempts have been made to study their struc-
tures (Parthier et al. 2007; Runge et al. 2008; Underwood
et al. 2010). In particular, studies aimed at probing the
interaction of the peptides with the N-terminus domain of
their receptors is of interest. Currently, nuclear magnetic
resonance (NMR) is the only technique that permits
determination of the structure of biomolecules at atomic-
level resolution in near-physiological conditions (solution
state) (Billeter et al. 2008; Banci et al. 2010). With isotopic
labeling, determining complex structures and studying the
interaction dynamics of biomolecules in the presence of
other biomolecules and within the cell is now feasible
(Stockman 2002; Takeuchi and Wagner 2006; Banci et al.
2010). However, much of the success of structural biology
depends on the availability of biomolecules in its utmost
pure and native state. Moreover, techniques such as X-ray
crystallography and NMR require proteins in mM
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concentration. With the advent of recombinant DNA
technology (rDNA) and techniques of gene synthesis,
affinity tag-based purification and subsequent removal of
the tag by protease cleavage, it is now possible to obtain
proteins in their native states with higher yields (Arnau
et al. 2006).
Expression of isotopic hGIP had not been reported till
date. The current study reports a method of isotopically
(15N)-labeled and unlabeled recombinant over-expression
of hGIP in pET32a(?) vector, with complete tag removal
by Factor Xa cleavage and purification of the native hGIP.
The peptide obtained here has been characterized by wes-
tern blotting using hGIP-specific antibody and the labeling
has been confirmed by MALDI.
Materials and methods
All the materials were obtained from Sigma-Aldrich India
Ltd., Merck-Millipore India, Himedia (India) and were of
molecular biology grade.
Designing the DNA construct for hgip gene
To overcome the problem of codon bias and facilitate
complete removal of the tags, the cDNA encoding hGIP
was commercially gene synthesized (First Base, Singapore)
with a nucleotide sequence coding for an Factor Xa pro-
tease cleavage at 50 and a stop codon at the 30 ends. The
cDNA was cloned into pET32a(?) and subsequently
transformed into Escherichia coli BL21(DE3) and E. coli
DH5a strains along with appropriate positive and negative
controls. The colonies grown in Luria–Bertani (LB) agar
plates containing ampicillin was checked for the presence
of the insert by colony PCR and the amplicons were
electrophoresed on a 2 % agarose gel containing ethidium
bromide. Glycerol stocks of the positive clones were pre-
pared and cryopreserved at -80 C. Plasmids were isolated
from the cells containing the construct and sequenced using
pET32a(?)-based primers.
Over-expression and purification of pET-GIP fusion
protein
The E. coli BL21(DE3) cells harboring the construct were
grown to an OD of 0.6 in 10 ml LB medium containing
ampicillin and induced using 1 mM IPTG. In order to
determine an optimum time of expression, induction was
carried out for 1, 3 and 18 h. The cells collected at different
time-points were harvested by centrifugation at 5,000g/
4 C and the expression of pET-GIP fusion protein was
checked by electrophoresing on a denaturing gel. The
solubility of the fusion protein was ascertained by
disrupting the cell lysate under non-denaturing conditions
and electrophoresing the supernatant (*100 lg total pro-
tein/lane) on a denaturing gel. The pET-GIP fusion protein
was confirmed using an antibody to the hexa-histidine
portion of the tag. Upon observing over-expression of the
23 kDa pET-GIP polypeptide on SDS-PAGE, the condi-
tions were scaled up to 1 l (culture volume) for 3 h and the
cells harvested by centrifugation at 5,000g for 10 min at
4 C. The cell pellets were stored at -80 C until the next
step of purification. At the time of purification, the pellet
was thawed and the cells were re-suspended in lysis buffer
(20 mM Tris–HCl buffer pH 7.5, 300 mM NaCl, 1 mM
PMSF, 10 % glycerol and 10 mM imidazole) and ruptured
by sonication. The supernatant was collected after centri-
fuging the cell lysate at 10,000g for 30 min at 4 C and
mixed with Ni–NTA beads that were pre-washed with the
lysis buffer, in a 50-ml centrifuge tube. The tube was kept
on a cell mixer and the binding of the fusion protein to the
beads was carried out for 2 h at 4 C. After binding, the
slurry was loaded on a BioRad elution column and the
flow-through was collected. The column was washed with
lysis buffer containing 20 mM imidazole to remove the
non-specific binding of proteins to the column. Elution of
the pET-GIP fusion protein was then carried out using
imidazole gradient from 20 mM to 2 M in the same buffer
and the various fractions were electrophoresed on a dena-
turing gel. The purity of the fusion protein was assessed by
silver staining of the gel. Subsequent purification of pET-
GIP fusion protein was carried out by the batch elution
method where the protein was eluted using 5 ml of lysis
buffer containing 100 mM, 500 mM and 1 M imidazole.
The fraction containing the protein was dialyzed against
the Factor Xa digestion buffer -20 mM Tris–HCl pH 6.5,
50 mM NaCl, 1 mM CaCl2 at 4 C.
Factor Xa cleavage of pET-GIP fusion protein
The cleavage of the purified pET-GIP fusion protein
obtained in the Factor Xa digestion buffer after dialysis
was optimized by varying parameters such as temperature
and enzyme concentration. The cleaved protein was elec-
trophoresed on a denaturing gel along with the uncleaved
control and molecular weight marker and different frag-
ments were observed. The fragments obtained upon
cleavage were also characterized by western blot using
hGIP-specific antibody to confirm the presence of the
peptide.
Purification of GIP from the mixture by gel filtration
The 5-kDa hGIP was purified at room temperature by
separating it from the mixture containing the residual tag
(18 kDa), other contaminants ([11 kDa) and Factor Xa
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enzyme (55 kDa) by gel filtration using a superdex 75
column on a GE AKTA FPLC system in 20 mM Tris–HCl
buffer (pH 7) 150 mM NaCl. The elution was monitored by
UV detector (280 nm) and elutes were collected as 2 ml
fractions. The fractions showing the protein were electro-
phoresed on 15 % SDS-PAGE and the separation was
checked.
Isotopic (15N) labeling and characterization of hGIP
by MALDI
Upon optimizing the basic strategies for over-expression,
tag removal and purification of hGIP, isotopic labeling of
the peptide was carried out by growing the E. coli
BL21(DE3) cells up to OD600 of 0.6 in the minimal med-
ium (M9) containing isotopic (15N) ammonium chloride as
the nitrogen source and induced using 1 mM IPTG. Sub-
sequent steps of purification were carried out in the manner
as reported for unlabeled hGIP.
The isotopic peptide (0.5 ll corresponding to 0.25 lg
concentration) was mixed with the non-isotopic hGIP
(0.5 ll corresponding to 0.4 lg concentration) in 1 ll of
Sinapinic acid as matrix and spotted on a ground steel
MALDI-TOF plate (Bruker Daltonics, USA). This mixture
was allowed to dry at room temperature and the plate was
then loaded into the instrument. Subsequent to adjusting
the appropriate parameters, the spot was fired using the
linear mode at 22 ± 2 C, 27 kV and a microchannel plate
detector. The molecular weight was determined using an
external standard (insulin, ubiquitin i, cytochrome c, myo-
globin that covered a mass range of *5,000–17,500 Da) at
an error of ±100 ppm, the software for deconvolution
being Flex analysis, Bruker Daltonics.
Results and discussion
The need to study the structure of biomolecules at near-
physiological conditions is mandatory for rational drug
design; hGIP being one of them. For this purpose, cel-
lular and molecular biologists as well as pharmacologists
have felt the need to obtain decent concentrations and
yields of hGIP in their studies. For long, such experi-
mentalists have been using either the synthetic peptide or
purifying it in bulk from natural sources (Pederson and
Brown 1976; Alan˜a et al. 2004). Besides, acquiring
(15N)hGIP or doubly labeled (15N, 13C)hGIP synthetically
for structural and/or receptor-binding studies has proven
to be cost intensive. The aim of the present study was to
obtain an economic and constant source of unlabeled and
labeled hGIP in reasonable yields using recombinant
DNA technology. The pET series of vectors have T7
promoters that over-express proteins in E. coli
BL21(DE3) cells (Studier and Moffatt 1986). Apart from
the hexa-histidine affinity tag, pET32a(?) also has a
localization tag (S-tag) and a solubilization tag (Thiore-
doxinA, TrxA) (Tsunoda et al. 2005). To prevent the
possibility of the protein routing into inclusion bodies,
the idea of tagging it with a TrxA tag was sought after.
The S-tag would aid in future receptor-binding studies
under physiological conditions. The current study has
directed efforts towards obtaining a constant source of
unlabeled as well as labeled hGIP. For the ultimate need
of obtaining a tag-less GIP, a construct was designed
suitably using pET32a(?) as the backbone vector. The
ThioredoxinA (TrxA) tag was followed by the Strepta-
vidin (S) tag, the hexa-histidine (6XHis) tag and a Factor
Xa cleavage site (IEGR). The GIP sequence was
Trax S 6His GIP






Fig. 1 Design of the construct resulting in the cloning of the GIP
ORF. a pET32a(?) plasmid (obtained from First Base, Singapore)
showing the position (between BamHI and HindIII) at which the hgip
insert was cloned. b A cartoon depiction of the Factor Xa cleavage
site. Note that upon cleavage the released hGIP is untagged. c PCR of
the hgip amplicon of *125 bp; lane labeled M is the standard
molecular weight marker, lane labeled A is the hgip amplicon
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introduced after this cleavage site so that the tag-less GIP
alone is released upon Factor Xa cleavage. The synthetic
sequence (Fig. 1a, b) so designed was then synthesized
commercially by First Base, Singapore. The resultant
recombinant vector (pET32a-fXa-gip) was used to trans-
form E. coli BL21(DE3) competent cells so as to yield
colonies on LB agar plates containing ampicillin as the
antibiotic of selection. Subsequent characterization by
colony PCR using insert-specific and vector-specific
primers showed desired amplicons on 2 % agarose gel
indicating the presence of the appropriate insert in all the
colonies (Fig. 1c). The sequencing of the plasmids iso-
lated from three such positive clones confirmed the pre-
sence of the correct sequence of the insert.
Over-expression and purification of pET-GIP fusion
protein
Escherichia coli BL21(DE3) strains containing the plasmid
(pET32a-fXa-gip) were induced with 1 mM IPTG. An
intense band of fusion protein (Trx-S-6XHis-fXa-GIP) was
observed at *23 kDa; the intensity of this band increased
with the duration of induction (Fig. 2a). The optimum time
for induction was found to be 3 h, beyond which the pro-
tein degraded. As expected, due entirely to the TrxA tag,
the fusion protein was found to be soluble as it was
released into the aqueous medium by non-denaturing cell
disruption (Fig. 2a; S for supernatant fraction that con-
tained the fusion protein and not in the pellet P). The
presence of the 6XHis tag, as confirmed using an anti-
6XHis antibody on a western blot of the fusion protein
(Fig. 2a; last lane) permitted affinity-based purification by
IMaC using Ni–NTA matrix.
M S   P  S   P  S   P  S  P   M   S













Fig. 2 Induction of the fusion protein (Trx-S-6XHis-fXa-GIP).
a Kinetics of the over-expression of the fusion protein, induction
with IPTG and detection of the 6XHis tag using an anti-hexa-histidine
antibody (denoted by a star in the last lane of this figure). b Affinity
(IMaC) based purification of the fusion protein using gradient elution
(20–2,000 mM imidazole). Note the purification of the fusion protein
in elutes 3 and 5. A silver stained gel of the purified protein (see
arrowhead). Lanes labeled M protein molecular weight standards,
P pellets, S supernatants obtained after extraction, UI uninduced
control, numbers time-points (in hours) of induction, FT flow-
through, W wash obtained after the proteins have been bound to the
column; numbers against arrows, molecular weights in kDa; pure,
purified protein (*5 lg)
M UD         D        UD        D
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d
Fig. 3 Factor Xa digestion and characterization by western blotting.
a The fusion protein (75 lg) was digested (lanes labeled D) with
Factor Xa and the digested products were electrophoresed on a
denaturing gel and silver stained; b Ponceau S staining of the
nitrocellulose membrane after transferring the digested products
(starting amount used was 200 lg) by the western blotting procedure;
c immunoblot for the detection of unlabeled hGIP (starting amount
used was 150 lg), and d labeled hGIP, using anti-hGIP antibodies.
UD and D labels in all the figures refer to undigested and digested,
respectively. The stars in all the figures show the position of the
digested product, viz. hGIP
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The purification of pET-hGIP fusion protein carried out
using Ni–NTA matrix and an imidazole gradient (20 mM–
2 M) showed the presence of pure 23 kDa fusion protein in the
elutes when electrophoresed on 15 % SDS-PAGE (Fig. 2b).
The protein eluted in the fraction corresponding to
*100–150 mM imidazole and subsequent batch purification
of the 15N-labeled fusion protein at 100, 250 and 1,000 mM
imidazole resulted in elution of maximum protein at 100 mM
(Fig. 2b).The silver stained gel showed *99 % purity and
absence of any contaminants. The yield of the fusion protein as
estimated by Bradford was found to be *30 mg/l culture
volume.
Factor Xa cleavage of the fusion protein, purification
by gel filtration and MALDI-TOF analysis
After obtaining the purified fusion protein, the conditions
for release of the GIP peptide after Factor Xa cleavage
were explored. The digestion with Factor Xa was found to
be optimum at pH 7.5, 4 C, enzyme concentration of
1 unit of protease and digestion time being 72 h (Fig. 3a).
Upon electrophoreses of the cleaved fragments on a 15 %
SDS-PAGE, distinct bands of Mr *18 kDa (corresponding
to the residual tags) and *5 kDa (corresponding to hGIP;
Fig. 3a) were observed. Another doublet of Mr *14 kDa
Fig. 4 a Isotopically labeled fusion protein was digested with Factor
Xa and the GIP was purified using gel filtration chromatography on
Superdex 75 column on an FPLC system (GE, AKTA). The inset is
the purified protein that was obtained after digestion. b Molecular
weight determination of unlabeled and isotopic (15N)GIP by MALDI
of unlabeled and isotopic (15N)GIP
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was also seen and possibly is a result of degradation of the
fusion protein. In order to ascertain the digested product as
hGIP (*5 kDa), a western blot of the digested products
was probed with the anti-hGIP antibody (Fig. 3b, c; hGIP
is marked with a star). This confirmed that the band was of
hGIP and also permitted for further purification of the
peptide.
The over-expression of the pET-hGIP fusion protein was
reproducible when the cells harboring the construct were
cultured in minimal media (M9) containing isotopic (15N)
ammonium chloride and induced using 1 mM IPTG. Sub-
sequently, the purification of pET-GIP fusion protein was
achieved successfully by affinity chromatography on a
Ni–NTA column. Although the labeled protein eluted at a
higher imidazole concentration (250 mM imidazole), the
conditions of digestion with Factor Xa were reproducible.
Further purification of hGIP was evident from the chro-
matogram where different fragments of the digested pET-
GIP protein separated differentially by gel filtration on a
Superdex 75 column, the tag and the doublet eluted in the
22nd–38th fraction (44–74 ml) and the hGIP at 41st–54th
fraction (82–108 ml) showing a peak in the 47th fraction
(94 ml). When the fraction corresponding to the hGIP peak
was loaded on 15 % SDS-PAGE it showed the hGIP
fragment in purified form (inset of Fig. 4a). The peptide
was concentrated by ultrafiltration using amicon column
mwco 3 kDa. The characterization of the labeled hGIP by
MALDI showed the desired peak precisely at 4.98 kDa
corresponding to the unlabeled peptide and also a peak at
5.44 kDa corresponding to the molecular weight of the 15N
labeled peptide. This confirmed the isotopic labeling of the
hGIP. The yield of the hGIP peptide was *1 mg/l of the
culture.
It may be noted that GIP (full-length) or truncated
versions have thus far been produced synthetically (Feh-
mann and Go¨ke 1995). Such synthetic peptides have been
used for various binding as well as physiological studies.
However, these have been useful in proton-NMR studies
and thus far no such method has been developed to obtain
isotopic (15N)hGIP. Hence, this is the first report of 15N-
labeled hGIP and we present a clone that harbors a fusion
gene containing the hgip gene that can be reproducibly
used to produce the fusion protein at *30 mg/l and upon
digestion and further purification, a peptide of almost 99 %
purity with a yield of *1 mg/l.
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